雪榕生物
(300511)
| 流通市值：27.57亿 | | | 总市值：31.02亿 |
| 流通股本：5.70亿 | | | 总股本：6.41亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,156,300,523.07 | 678,923,162.65 | 1,987,614,708.05 | 1,324,930,751.78 |
| 营业总成本 | 1,078,939,727.76 | 505,757,763.08 | 1,955,920,414.81 | 1,403,701,115.19 |
| 其他经营收益 | | | | |
| 营业利润 | 14,459,331.94 | 175,950,207.39 | 42,652,078.79 | -53,581,230.12 |
| 利润总额 | 13,937,119.93 | 175,699,775.93 | 39,194,111.09 | -55,447,177.36 |
| 净利润 | 13,725,364.97 | 175,651,463.36 | 38,418,736.45 | -56,207,159.98 |
| 每股收益 | | | | |
| 其他综合收益 | -3,308,407.86 | -2,155,034.21 | 1,062,270.97 | 764,947.24 |
| 综合收益总额 | 10,416,957.11 | 173,496,429.15 | 39,481,007.42 | -55,442,212.74 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 606,670,089.95 | 774,259,630.77 | 606,040,628.1 | 545,231,190.83 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,919,863,944.63 | 2,934,499,574.88 | 2,995,323,705.1 | 3,056,209,472.11 |
| 资产总计 | 3,526,534,034.58 | 3,708,759,205.65 | 3,601,364,333.2 | 3,601,440,662.94 |
| 流动负债: | | | | |
| 流动负债合计 | 1,632,841,013.68 | 1,177,063,179.31 | 1,756,797,899.86 | 1,353,085,933.97 |
| 非流动负债: | | | | |
| 非流动负债合计 | 361,274,647.86 | 843,634,384.84 | 331,079,640.81 | 899,545,374.43 |
| 负债合计 | 1,994,115,661.54 | 2,020,697,564.15 | 2,087,877,540.67 | 2,252,631,308.4 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,635,102,155.12 | 1,783,972,428.92 | 1,612,021,158.06 | 1,456,940,504.02 |
| 股东权益合计 | 1,532,418,373.04 | 1,688,061,641.5 | 1,513,486,792.53 | 1,348,809,354.54 |
| 负债和股东权益合计 | 3,526,534,034.58 | 3,708,759,205.65 | 3,601,364,333.2 | 3,601,440,662.94 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,176,922,590.55 | 691,219,713.37 | 1,982,410,115.04 | 1,348,760,781.48 |
| 经营活动现金流出小计 | 955,936,922.15 | 487,618,247.73 | 1,566,561,988.39 | 1,100,603,837.8 |
| 经营活动产生的现金流量净额 | 220,985,668.4 | 203,601,465.64 | 415,848,126.65 | 248,156,943.68 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 5,183,845.21 | 654,697.34 | 30,188,465.48 | 16,487,467.88 |
| 投资活动现金流出小计 | 139,708,244.16 | 72,568,778.67 | 79,587,860.55 | 59,319,655.16 |
| 投资活动产生的现金流量净额 | -134,524,398.95 | -71,914,081.33 | -49,399,395.07 | -42,832,187.28 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 312,950,000 | 161,050,000 | 556,999,383.18 | 423,140,000 |
| 筹资活动现金流出小计 | 402,607,952.35 | 164,133,890.2 | 914,509,796.6 | 673,477,152.32 |
| 筹资活动产生的现金流量净额 | -89,657,952.35 | -3,083,890.2 | -357,510,413.42 | -250,337,152.32 |
| 汇率变动对现金及现金等价物的影响 | -314,558.17 | -1,074,410.07 | 259,737.37 | 39,063.65 |
| 现金及现金等价物净增加额 | -3,511,241.07 | 127,529,084.04 | 9,198,055.53 | -44,973,332.27 |
| 期末现金及现金等价物余额 | 155,628,331.08 | 286,668,656.19 | 159,139,572.15 | 104,968,184.35 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -3,511,241.07 | - | 9,198,055.53 | - |